View Clinical Trial (Medical Research Study)
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Avastin in Patients With Metastatic Colorectal Cancer After Failure of One First Line Regimen. - NCT00615056-34223(Clinical Trial 202503)
ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.
| City: |
|
Englewood |
|
State:
|
|
FL |
| Zip Code: |
|
34223 |
| Conditions: |
|
Colorectal Neoplasms |
| Purpose: |
|
The study is designed to demonstrate that the combination of AG-013736 with either FOLFIRI
or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab in delaying tumor
progression in the second-line treatment of patients with metastatic colorectal cancer after
failure of an irinotecan or oxaliplatin-containing first-line regimen
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Histologically documented colorectal cancer plus one of the following:
- Failure of one prior irinotecan- or oxaliplatin-containing regimen, or
- Adjuvant refractory to irinotecan- or oxaliplatin-containing regimen.
Exclusion Criteria:
- Prior treatment in first line metastatic setting with more than one regimen
- Prior irradiation of more than 25% of bone marrow. |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
February 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|